BACKGROUND: In sub-Saharan Africa, gonococcal and chlamydial infections are usually managed using the syndromic approach. However, many infections are asymptomatic in women, and the syndromic algorithm has poor sensitivity and specificity for infections caused by Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). Because of this, rapid point of care (POC) tests for Ct/Ng could improve sexually transmitted infection (STI) management in women. This study uses mathematical modelling to estimate the incremental cost effectiveness of using POC tests to diagnose Ng/Ct instead of the current syndromic approach used by the SIDA2 HIV/STI prevention project for female sex workers in Cotonou, Benin. METHODS: A dynamic mathematical model was used with data from Cotonou to estimate the HIV impact of the existing SIDA2 project (1995-8), and to project how impact would change if POC tests had been used. As observed in test evaluations, the POC tests were assumed to have high specificity, but a range of sensitivities. The incremental economic cost effectiveness of using POC tests was modelled using data on intervention costs and an evaluation of an Ng POC test in Cotonou in 2004. All costs were in 2004 US dollars. RESULTS: The model estimated the STI treatment aspect of the intervention averted 18 553 Ng/Ct and 359 HIV infections over 4 years when the syndromic approach was used. In contrast, if Ng/Ct had been diagnosed with a 70-80% sensitive and 95% specific POC test then 24-31% fewer clinic attenders would have been treated, 40-60% more Ng/Ct and HIV infections would have been averted, and the incremental cost effectiveness of using them would have been 107-151 dollars per HIV infection averted if the POC tests cost 2 dollars and 58-81 dollars if they cost 1 dollar. CONCLUSIONS: POC tests can be a cost effective strategy for substantially increasing the impact on HIV transmission, and decreasing the degree of inappropriate treatment of STI treatment interventions that use syndromic management to diagnose Ng/Ct.
BACKGROUND: In sub-Saharan Africa, gonococcal and chlamydial infections are usually managed using the syndromic approach. However, many infections are asymptomatic in women, and the syndromic algorithm has poor sensitivity and specificity for infections caused by Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). Because of this, rapid point of care (POC) tests for Ct/Ng could improve sexually transmitted infection (STI) management in women. This study uses mathematical modelling to estimate the incremental cost effectiveness of using POC tests to diagnose Ng/Ct instead of the current syndromic approach used by the SIDA2 HIV/STI prevention project for female sex workers in Cotonou, Benin. METHODS: A dynamic mathematical model was used with data from Cotonou to estimate the HIV impact of the existing SIDA2 project (1995-8), and to project how impact would change if POC tests had been used. As observed in test evaluations, the POC tests were assumed to have high specificity, but a range of sensitivities. The incremental economic cost effectiveness of using POC tests was modelled using data on intervention costs and an evaluation of an Ng POC test in Cotonou in 2004. All costs were in 2004 US dollars. RESULTS: The model estimated the STI treatment aspect of the intervention averted 18 553 Ng/Ct and 359 HIV infections over 4 years when the syndromic approach was used. In contrast, if Ng/Ct had been diagnosed with a 70-80% sensitive and 95% specific POC test then 24-31% fewer clinic attenders would have been treated, 40-60% more Ng/Ct and HIV infections would have been averted, and the incremental cost effectiveness of using them would have been 107-151 dollars per HIV infection averted if the POC tests cost 2 dollars and 58-81 dollars if they cost 1 dollar. CONCLUSIONS: POC tests can be a cost effective strategy for substantially increasing the impact on HIV transmission, and decreasing the degree of inappropriate treatment of STI treatment interventions that use syndromic management to diagnose Ng/Ct.
Authors: H Chakraborty; P K Sen; R W Helms; P L Vernazza; S A Fiscus; J J Eron; B K Patterson; R W Coombs; J N Krieger; M S Cohen Journal: AIDS Date: 2001-03-30 Impact factor: 4.177
Authors: C M Lowndes; M Alary; C A Gnintoungbé; E Bédard; L Mukenge; N Geraldo; P Jossou; E Lafia; F Bernier; E Baganizi; J Joly; E Frost; S Anagonou Journal: AIDS Date: 2000-11-10 Impact factor: 4.177
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: S A Allen; R Musonda; S Trask; B H Hahn; H Weiss; J Mulenga; F Kasolo; S H Vermund; G M Aldrovandi Journal: AIDS Res Hum Retroviruses Date: 2001-07-01 Impact factor: 2.205
Authors: Peter Vickerman; Charlotte Watts; Sinead Delany; Michel Alary; Helen Rees; Lori Heise Journal: Sex Transm Dis Date: 2006-06 Impact factor: 2.830
Authors: M Sabidó; G Hernández; V González; X Vallès; A Montoliu; J Figuerola; V Isern; B Viñado; L Figueroa; J Casabona Journal: J Clin Microbiol Date: 2008-12-03 Impact factor: 5.948
Authors: Sharmistha Mishra; Marie-Claude Boily; Sheree Schwartz; Chris Beyrer; James F Blanchard; Stephen Moses; Delivette Castor; Nancy Phaswana-Mafuya; Peter Vickerman; Fatou Drame; Michel Alary; Stefan D Baral Journal: Ann Epidemiol Date: 2016-06-15 Impact factor: 3.797
Authors: M Romoren; F Hussein; T W Steen; M Velauthapillai; J Sundby; P Hjortdahl; I S Kristiansen Journal: Sex Transm Infect Date: 2007-10-11 Impact factor: 3.519
Authors: Matthew F Chersich; Stanley Luchters; Innocent Ntaganira; Antonio Gerbase; Ying-Ru Lo; Fiona Scorgie; Richard Steen Journal: J Int AIDS Soc Date: 2013-03-04 Impact factor: 5.396